CDXS
Price
$2.35
Change
+$0.11 (+4.89%)
Updated
Apr 11, 04:59 PM (EDT)
Capitalization
187.63M
20 days until earnings call
DNLI
Price
$12.70
Change
+$0.20 (+1.60%)
Updated
Apr 11, 04:59 PM (EDT)
Capitalization
1.82B
32 days until earnings call
Ad is loading...

CDXS vs DNLI

Header iconCDXS vs DNLI Comparison
Open Charts CDXS vs DNLIBanner chart's image
Codexis
Price$2.35
Change+$0.11 (+4.89%)
Volume$15.34K
Capitalization187.63M
Denali Therapeutics
Price$12.70
Change+$0.20 (+1.60%)
Volume$20.45K
Capitalization1.82B
CDXS vs DNLI Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. DNLI commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (CDXS: $2.25 vs. DNLI: $12.50)
Brand notoriety: CDXS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 92% vs. DNLI: 99%
Market capitalization -- CDXS: $187.63M vs. DNLI: $1.82B
CDXS [@Biotechnology] is valued at $187.63M. DNLI’s [@Biotechnology] market capitalization is $1.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $263.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDXS and DNLI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а -1.75% price change this week, while DNLI (@Biotechnology) price change was -2.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.88%. For the same industry, the average monthly price growth was -13.10%, and the average quarterly price growth was -15.11%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 31, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.82B) has a higher market cap than CDXS($188M). DNLI YTD gains are higher at: -38.665 vs. CDXS (-52.830). CDXS has higher annual earnings (EBITDA): -53.41M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. CDXS (73.5M). DNLI has less debt than CDXS: DNLI (48.7M) vs CDXS (59.9M). CDXS has higher revenues than DNLI: CDXS (59.3M) vs DNLI (0).
CDXSDNLICDXS / DNLI
Capitalization188M1.82B10%
EBITDA-53.41M-492.89M11%
Gain YTD-52.830-38.665137%
P/E RatioN/AN/A-
Revenue59.3M0-
Total Cash73.5M832M9%
Total Debt59.9M48.7M123%
FUNDAMENTALS RATINGS
CDXS vs DNLI: Fundamental Ratings
CDXS
DNLI
OUTLOOK RATING
1..100
5863
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9538
PRICE GROWTH RATING
1..100
8890
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (44) in the Chemicals Specialty industry is somewhat better than the same rating for DNLI (94) in the Biotechnology industry. This means that CDXS’s stock grew somewhat faster than DNLI’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as DNLI (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for CDXS (95) in the Chemicals Specialty industry. This means that DNLI’s stock grew somewhat faster than CDXS’s over the last 12 months.

CDXS's Price Growth Rating (88) in the Chemicals Specialty industry is in the same range as DNLI (90) in the Biotechnology industry. This means that CDXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (97) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that DNLI’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 26 days ago
85%
Bullish Trend 15 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDECX19.20N/A
N/A
Fidelity Advisor Capital Development C
SLPIX98.03N/A
N/A
ProFunds Small Cap Inv
OBSOX22.32N/A
N/A
Oberweis Small-Cap Opportunities
QASGX22.31N/A
N/A
Federated Hermes MDT Small Cap Growth A
LGCVX15.95N/A
N/A
Lord Abbett Global Equity R5

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-2.60%
DNLI - CDXS
49%
Loosely correlated
-2.80%
ABCL - CDXS
44%
Loosely correlated
-4.61%
PRAX - CDXS
44%
Loosely correlated
-7.71%
XENE - CDXS
43%
Loosely correlated
-2.72%
AXON - CDXS
43%
Loosely correlated
-1.53%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.80%
RCKT - DNLI
60%
Loosely correlated
-8.52%
BEAM - DNLI
58%
Loosely correlated
-10.63%
NTLA - DNLI
56%
Loosely correlated
-4.38%
ARWR - DNLI
56%
Loosely correlated
-5.85%
CRSP - DNLI
54%
Loosely correlated
-1.81%
More